Octreotide

FDA Drug Profile — Mycapssa

Octreotide is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand name including Mycapssa. Available dosage forms: powder, capsule, delayed release.

Drug details

Generic Name
Octreotide
Brand Names
Mycapssa
Application Number
NDA208232
Sponsor
Bachem Americas, Inc.
NDC Codes
7
Dosage Forms
POWDER, CAPSULE, DELAYED RELEASE
Routes
ORAL
Active Ingredients
OCTREOTIDE ACETATE, OCTREOTIDE

Indications and Usage

1 INDICATIONS AND USAGE MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide (‎ 1 ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.